Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK39297 PK in Hepatic Impairment
NCT07152288Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ciprocopan in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to time t and 1 more. Started May 2025; status: recruiting.
02
Drugs
ciprocopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07152288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152288.